A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501

Overview of attention for article published in Advances in Therapy, June 2019

Altmetric Badge

About this Attention Score

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 2,639 followers.

RT @AdvancesTherapy: Just published: "A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar AB…

Just published: "A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501" #Biosimilars #Rheumatology #Immunology. Read the full paper here: https://t.co/8Ubhzfluqb https://t.co/NxuakNpDA0